Harmony Biosciences (HRMY) Tops Q4 EPS by 28c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.63, $0.28 better than the analyst estimate of $0.35. Revenue for the quarter came in at $91.2 million versus the consensus estimate of $91.33 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• RH (RH) Tops Q1 EPS by 12c